AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00708565
Drug: iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
Trial: NCT04232553
Drug: Mirikizumab
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04232553
Drug: Mirikizumab
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01052844
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
Trial: NCT04565184
Drug: Artesunate-amodiaquine combination
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
Trial: NCT03924856
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
Trial: NCT03924856
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle
Trial: NCT03924856
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle
Trial: NCT01224210
Drug: Ambrisentan
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
Trial: NCT00509210
Drug: telaprevir (VX-950)
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05086081
Drug: Ticagrelor 90mg
RxNorm normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any ticagrelor dispensing claim is used as the exposure group
Trial: NCT05086081
Drug: Prasugrel 10mg
RxNorm normalized name: Prasugrel 10mg Oral tablet
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Any prasugrel dispensing claim is used as the reference group
Trial: NCT00270829
Drug: nesiritide
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug given intrarenally or placebo
Trial: NCT01133561
Drug: actozone A
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone 30 mg tablet , once daily dose for 10 weeks
Trial: NCT01133561
Drug: actozone B
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of vehicle without active ingredient pioglitazone
Trial: NCT04365257
Drug: Prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive the study drug as outlined in the arm description.
Trial: NCT00454701
Drug: Alefacept exposure
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observational
Trial: NCT00368329
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2 continuous venous infusion
Trial: NCT00368329
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 2, based onCalvert formula IV infusion
Trial: NCT03628352
Drug: Tricaprilin
RxNorm normalized name: TRICAPRILIN
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricaprilin with flavoring agents added
Trial: NCT00630474
Drug: xylometazoline
RxNorm normalized name: XYLOMETAZOLINE
DrugBank: Xylometazoline (DB06694)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
Trial: NCT00117286
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
Trial: NCT04354727
Drug: APG-1252
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion once weekly
Trial: NCT03039751
Drug: Control Rx
RxNorm normalized name: Control Rx
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
Trial: NCT02076191
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.
Trial: NCT02076191
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
Trial: NCT04354727
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: taken orally twice a day
Trial: NCT01374711
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
Trial: NCT01374711
Drug: IFN-Y
RxNorm normalized name: Interferon gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
Trial: NCT00961766
Drug: BG00010 (Neublastin)
RxNorm normalized name: NEUBLASTIN
DrugBank: Artemin (DB15438)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, weight-based IV administration
Trial: NCT02690558
Drug: pembrolizumab, gemcitabine and cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
Trial: NCT01814137
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
Trial: NCT01814137
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
Trial: NCT01814137
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
Trial: NCT04115644
Drug: Marcaine (placebo)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
Trial: NCT04115644
Drug: Kenalog
RxNorm normalized name: Kenalog
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
Trial: NCT04222972
Drug: Pralsetinib
RxNorm normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally
Trial: NCT01814137
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
Trial: NCT04222972
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT04222972
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04222972
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IV
Trial: NCT04222972
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT04222972
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT04222972
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT04222972
Drug: Nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT00219557
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
Trial: NCT00219557
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
Trial: NCT00219557
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
Trial: NCT00130481
Drug: Atorvastatin 20 mg daily for 3 months
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01484990
Drug: Levodopa-Carbidopa
RxNorm normalized name: carbidopa / levodopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intestinal Gel
Trial: NCT03077633
Drug: Vaginal Progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
Trial: NCT00428194
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m\^2 every 7 days during radiation
Trial: NCT02009007
Drug: phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous infusion of phenylephrine during operation
Trial: NCT02343081
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00925990
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
Trial: NCT04258943
Drug: Bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with R/I disease are enrolled at a dose of 400 mg/m2 (DL2B) based on tolerability and PK analysis. Once the RP2D for R/I patients (RP2DR/I) is determined in the Phase 1, subsequent patients with R/I disease will be enrolled at the RP2DR/I for this subpopulation for the Phase 2 component of the study (see section 1.6.3 and section 3 for details).~- Patients with newly diagnosed disease are being enrolled on Phase 2 component only, at RP2DND dose of 300 mg/m2. (see section 1.6.3 and section 3 for details)
Trial: NCT01995578
Drug: low dose 5'-azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
Trial: NCT00925990
Drug: CTS-1027
RxNorm normalized name: CTS-1027
DrugBank: CTS-1027 (DB08490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
Trial: NCT00925990
Drug: Placebo for ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsules identical to ribavirin in appearance containing inactive ingredients
Trial: NCT00956956
Drug: PF-04455242
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
Trial: NCT02688790
Drug: Dalbavancin
RxNorm normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00428194
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m\^2 by mouth once a day beginning day 1.
Trial: NCT00969904
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg TID for 12 weeks
Trial: NCT01375335
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
Trial: NCT00004912
Drug: megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03690453
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of Ivermectin
Trial: NCT02794740
Drug: X0002
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: External Spray
Trial: NCT02057393
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
Trial: NCT02057393
Drug: Technetium99
RxNorm normalized name: technetium
DrugBank: Technetium Tc-99m (DB14227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
Trial: NCT02057393
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
Trial: NCT02675231
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered Orally
Trial: NCT02675231
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT02675231
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IM
Trial: NCT02238977
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant
Trial: NCT01504867
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.
Trial: NCT00571922
Drug: Acamprosate
RxNorm normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 gr/day (333 mg, TID)
Trial: NCT05438641
Drug: BZDP-Sparing Protocol
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants). Rescue with BZDP-based treatment allowed if there is symptomatic breakthrough- as measured by CIWA \> 15.
Trial: NCT04714099
Drug: Topical Cyclosporine A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In our study we used 0.05% CsA prepared in castor oil by transferring (20ml ) of sterile castor oil in a sterile glass vial under laminar flow, removing a volume (400ul)of oil with micropipette (sterile tips), and replacing this volume with an equal volume of alcoholic CsA solution \[200mg cyclosporine in 8 ml ethanol (96%)\] under laminar flow.
Trial: NCT01841359
Drug: Pramlintide
RxNorm normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See description above (arm description).
Trial: NCT04368585
Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
RxNorm normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
Trial: NCT04368585
Drug: 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.
Trial: NCT04368585
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg (1 x 40 mg capsule) omeprazole administered QD
Trial: NCT01254045
Drug: oxytocin 24IU
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
Trial: NCT01254045
Drug: oxytocin 48IU
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal oxytocin (48 international units)
Trial: NCT01620489
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
Trial: NCT00003633
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003633
Drug: estramustine phosphate sodium
RxNorm normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003633
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003633
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00360867
Drug: AMG 706
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.